Targeting specific microRNAs to prevent liver cancer development
MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma
This study is looking at how tiny molecules called microRNAs can help change liver immune cells to stop liver cancer from developing, and it's being tested in mice to find new treatments for people with liver cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10903824 on NIH RePORTER |
What this research studies
This research investigates how microRNAs, specifically miR-15a and miR-16, can be used to reprogram immune cells in the liver, known as Kupffer cells, to prevent the development of hepatocellular carcinoma (HCC). The study utilizes a mouse model where these microRNAs are introduced to see if they can reverse the immune suppression that allows cancer to grow. By understanding the mechanisms involved, the research aims to develop new therapeutic strategies for HCC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for hepatocellular carcinoma, particularly those with chronic liver disease or cirrhosis.
Not a fit: Patients with liver cancer that has already progressed to advanced stages may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly reduce the risk of liver cancer in patients.
How similar studies have performed: Previous research has shown promising results in using microRNA therapies to influence cancer progression, indicating potential for success in this approach.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Song, Guisheng — University of Minnesota
- Study coordinator: Song, Guisheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.